However, our results suggest the potential value of CSPG4-CAR.CIKs treatment in GIST, notably “CSPG4-high” tumors, that calls for drug testing in vivo, and then in clinical trials. Here, TRAF3IP2 is linked to gastrointestinal stromal tumor.